Adult T-Cell Leukemia/lymphoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

ATLL MCID: ADL104 MIFTS: 52	Adult T-Cell Leukemia/lymphoma (ATLL) Categories: Blood diseases, Cancer diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Adult T-Cell Leukemia/lymphoma

MalaCards integrated aliases for Adult T-Cell Leukemia/lymphoma:

Name: Adult T-Cell Leukemia/lymphoma ¹¹ ¹⁹ ⁵⁸ ³⁶ ⁷⁵

Adult T-Cell Leukemia ¹¹ ¹⁴

Atll ¹⁹ ⁵⁸

Adult T-Cell Leukaemia/lymphoma ¹⁹

Leukemia-Lymphoma, Adult T-Cell ⁴³

T Cell Leukemia Lymphoma Adult ⁵³

Adult T-Cell Lymphoma/leukemia ⁷¹

Adult T-Cell Leukaemia ¹⁹

Adult T-Cell Lymphoma ¹⁹

Leukemia, T-Cell ⁷¹

Characteristics:

Inheritance:

Multigenic/multifactorial ⁵⁸

Prevelance:

1-9/100000 (Europe) ⁵⁸

Age Of Onset:

Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Infectious diseases
Anatomical: Skin diseases Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Lymphoid leukaemia

Adult T-cell lymphoma/leukaemia (HTLV-1-associated)

Orphanet: ⁵⁸

Rare skin diseases

Rare haematological diseases

External Ids:

Disease Ontology ¹¹ DOID:0050523

MeSH ⁴³ D015459

NCIt ⁴⁹ C3184

SNOMED-CT ⁶⁸ 77430005

ICD10 ³¹ C91.5

MESH via Orphanet ⁴⁴ D015459

ICD10 via Orphanet ³² C91.5

UMLS via Orphanet ⁷² C0023493

Orphanet ⁵⁸ ORPHA86875

UMLS ⁷¹ C0023492 C0023493

Sources

Summaries for Adult T-Cell Leukemia/lymphoma

GARD: ¹⁹ Adult T-cell leukemia/lymphoma (ATL) is is a rare and aggressive T-cell lymphoma that is linked to infection by the human T-cell lymphotropic virus 1 (HTLV-1). The exact mechanism by which HTLV-I infection causes the ATL is unknown. The clinical features of ATL include generalized swelling of the lymph nodes (lymphadenopathy), increased liver and spleen size (hepatosplenomegaly), immunosuppression, high levels of calcium in the blood, lytic bone lesions (spots that appear as 'holes' on a standard bone x-ray), and skin lesions. There are four basic clinical variants of ATL: acute (60% of cases), lymphomatous (20 % of cases), chronic (10% of cases) and smoldering (10% of cases).

MalaCards based summary: Adult T-Cell Leukemia/lymphoma, also known as adult t-cell leukemia, is related to t-cell adult acute lymphocytic leukemia and t-cell acute lymphoblastic leukemia. An important gene associated with Adult T-Cell Leukemia/lymphoma is BCL11B (BCL11 Transcription Factor B), and among its related pathways/superpathways are NF-kappaB Signaling and CD28 Signaling in T-Helper Cell. The drugs Zidovudine and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and bone, and related phenotypes are immune system and hematopoietic system

Orphanet: ⁵⁸ A rare, virus associated tumor due to human T-cell leukemia virus type 1 or human T-cell lymphotropic virus type 1 (HTLV-1) and is characterized by the presence of anti-HTLV-1 antibodies, and malignant, mature, medium-sized T cells with condensed chromatin and polylobated nuclei. The malignant cells exhibit a mature CD4+ T cells phenotype and express CD2, CD5, CD25, CD45RO, HLA-DR, and T-cell receptor αβ. Presentation is heterogeneous and is typically of aggressive leukemia or lymphoma, variable skin eruptions, and visceral organ involvement.

Disease Ontology: ¹¹ A T-cell acute leukemia that results in abnormal increase of lymphocytes, derives from T-cells, has material basis in Human T-lymphotropic virus 1 (HTLV-1), which is transmitted by sexual contact, transmitted by contaminated needles used by intravenous-drug users, and transmitted by breast feeding. The infection results in formation of skin lesions.

Wikipedia: ⁷⁵ Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood... more...

Sources

Related Diseases for Adult T-Cell Leukemia/lymphoma

Diseases related to Adult T-Cell Leukemia/lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 930)

#	Related Disease	Score	Top Affiliating Genes
1	t-cell adult acute lymphocytic leukemia	32.3	TNFRSF8 MIR28 IL2 HBZ CNTN2 CENPV
2	t-cell acute lymphoblastic leukemia	31.8	TNFRSF8 PTHLH MIR155 KDM4C IL2RA IL2
3	mycosis fungoides	31.6	TNFRSF8 MIR155 IL2RA IL2 CD7 CCR6
4	fungal infectious disease	31.6	IL2 ICOSLG H2AC18 CD8A CD4 CCR6
5	tropical spastic paraparesis	31.6	IL2RA IL2 HBZ CNTN2 CENPV CD8A
6	acute graft versus host disease	31.5	IL2RA IL2
7	spinal cord disease	31.4	MIR155 KDM4C ICOSLG HBZ H2AC18 CD8A
8	strongyloidiasis	31.4	HBZ CD7 CD4
9	lymphoma, hodgkin, classic	31.4	TNFRSF8 MIR155 KDM4C IL2RA IL2 ICOSLG
10	exanthem	31.3	IL2 ICOSLG H2AC18 CD8A CD4 CCR6
11	scabies	31.2	TNFRSF8 CD8A CD4 CCR6
12	human cytomegalovirus infection	31.1	CD8A CD4 CCR6
13	lymphadenitis	31.1	IL2RA ICOSLG CCR6
14	primary cutaneous t-cell non-hodgkin lymphoma	31.1	TNFRSF8 MIR155 KDM4C IL2RA IL2 H2AC18
15	norwegian scabies	31.1	CD8A CD4
16	severe cutaneous adverse reaction	31.1	CD8A CD4 CCR6
17	pneumocystosis	31.1	IL2 CD8A CD4 CCR6
18	peripheral t-cell lymphoma	31.0	TNFRSF8 MIR155 KDM4C IL2RA ICOSLG H2AC18
19	respiratory failure	31.0	MIR155 IL2 H2AC18 CD8A CD4 CCR6
20	sezary's disease	31.0	TNFRSF8 MIR155 IL2RA IL2 CD8A CD7
21	herpes zoster	31.0	IL2 CD8A CD4 CCR6
22	severe combined immunodeficiency	30.9	TNFRSF8 IL2RA IL2 ICOSLG H2AC18 CD8A
23	hematologic cancer	30.9	TNFRSF8 PTHLH MIR28 MIR155 KDM4C IL2RA
24	lymphoblastic lymphoma	30.9	TNFRSF8 CD8A CD7
25	follicular mucinosis	30.9	TNFRSF8 CD8A CD7 CD4 CD2
26	pancytopenia	30.9	IL2RA H2AC18 CD8A CD7 CD4 CD2
27	cryptococcosis	30.9	CD8A CD4 CCR6
28	t-cell prolymphocytic leukemia	30.9	TNFRSF8 H2AC18 CD8A CD7 CD4 CD2
29	henoch-schoenlein purpura	30.9	ICOSLG CD4 CCR6
30	pfeiffer syndrome	30.8	TNFRSF8 IL2 H2AC18 CD8A CD4 CCR6
31	bacterial sepsis	30.8	ICOSLG CD8A CD4 CCR6
32	cryptococcal meningitis	30.8	IL2 CD8A CD4 CCR6
33	diffuse large b-cell lymphoma	30.8	TNFRSF8 MIR28 MIR155 KDM4C ICOSLG H2AC18
34	viral infectious disease	30.8	MIR155 IL2RA IL2 ICOSLG H2AC18 CD4
35	intestinal perforation	30.7	CD8A CD4 CCR6
36	alopecia areata	30.7	IL2RA IL2 ICOSLG
37	miliary tuberculosis	30.7	IL2 CD8A CD4
38	hemorrhagic cystitis	30.7	IL2 CD8A CD4
39	filarial elephantiasis	30.7	IL2 CD8A CD4
40	demyelinating polyneuropathy	30.7	CNTN2 CD8A CD4
41	oral candidiasis	30.7	CD8A CD4 CCR6
42	intermediate uveitis	30.7	IL2RA IL2 CD4 CCR6
43	acute retinal necrosis syndrome	30.7	CD8A CD4
44	nasal type extranodal nk/t-cell lymphoma	30.7	TNFRSF8 KDM4C CD2
45	keratoconjunctivitis sicca	30.7	ICOSLG CD4 CCR6
46	central nervous system lymphoma	30.6	TNFRSF8 KDM4C CD4
47	lymphoma, non-hodgkin, familial	30.6	TNFRSF8 MIR28 MIR155 KDM4C IL2RA IL2
48	viral pneumonia	30.6	IL2 CD8A CD4 CCR6
49	chickenpox	30.6	IL2 CD8A CD4 CCR6
50	severe covid-19	30.6	IL2 CD8A CD4 CCR6

Graphical network of the top 20 diseases related to Adult T-Cell Leukemia/lymphoma:

Sources

Symptoms & Phenotypes for Adult T-Cell Leukemia/lymphoma

MGI Mouse Phenotypes related to Adult T-Cell Leukemia/lymphoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	9.8	ATL2 BCL11B CCR6 CD4 CD7 CD8A
2	hematopoietic system	MP:0005397	9.5	ATL2 BCL11B CCR6 CD4 CD7 CD8A

Sources

Drugs & Therapeutics for Adult T-Cell Leukemia/lymphoma

Drugs for Adult T-Cell Leukemia/lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Zidovudine

Approved

Phase 4

30516-87-1

35370

Peginterferon alfa-2b

Approved

Phase 4

215647-85-1, 99210-65-8

Valproic acid

Approved, Investigational

Phase 4

99-66-1

3121

Daclizumab

Investigational, Withdrawn

Phase 4

152923-56-3

Antimetabolites

Phase 4

Immunologic Factors

Phase 4

Reverse Transcriptase Inhibitors

Phase 4

Interferon alpha-2

Phase 4

interferons

Phase 4

Interferon-alpha

Phase 4

Neurotransmitter Agents

Phase 4

Psychotropic Drugs

Phase 4

Anticonvulsants

Phase 4

Idarubicin

Approved

Phase 2, Phase 3

58957-92-9

42890

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Cytarabine

Approved, Investigational

Phase 3

147-94-4

6253

Decitabine

Approved, Investigational

Phase 3

2353-33-5

451668

Aclarubicin

Investigational

Phase 3

57576-44-0

Adjuvants, Immunologic

Phase 3

homoharringtonine

Phase 3

3628

Prednisone

Approved, Vet_approved

Phase 1, Phase 2

53-03-2

5865

Miconazole

Approved, Investigational, Vet_approved

Phase 1, Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 1, Phase 2

23593-75-1

2812

Iron

Approved

Phase 2

7439-89-6

29936

Deferasirox

Approved, Investigational

Phase 2

201530-41-8

214348 5493381

Mechlorethamine

Approved, Investigational

Phase 2

51-75-2

4033

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Everolimus

Approved

Phase 1, Phase 2

159351-69-6

70789204 6442177

Sirolimus

Approved, Investigational

Phase 1, Phase 2

53123-88-9

5284616 6436030

Alemtuzumab

Approved, Investigational

Phase 2

216503-57-0

Vindesine

Approved, Investigational

Phase 2

59917-39-4, 53643-48-4

40839

Triamcinolone

Approved, Vet_approved

Phase 1, Phase 2

124-94-7

31307

Edetate calcium disodium anhydrous

Approved, Vet_approved

Phase 1, Phase 2

62-33-9, 60-00-4

6049

Pentetic acid

Approved

Phase 1, Phase 2

67-43-6

Lamivudine

Approved, Investigational

Phase 2

134678-17-4

60825

Cladribine

Approved, Investigational

Phase 2

4291-63-8

20279

Irinotecan

Approved, Investigational

Phase 2

97682-44-5, 100286-90-6

60838

Belinostat

Approved, Investigational

Phase 2

414864-00-9, 866323-14-0

53437714 6918638

Gemcitabine

Approved

Phase 2

95058-81-4, 122111-03-9

60750

Azacitidine

Approved, Investigational

Phase 2

320-67-2

9444

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Thiotepa

Approved, Investigational

Phase 2

52-24-4

5453

Lomustine

Approved, Investigational

Phase 2

13010-47-4

3950

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Venetoclax

Approved, Investigational

Phase 2

1257044-40-8

49846579

Picropodophyllin

Approved, Investigational

Phase 2

518-28-5, 477-47-4

10607 72435

Daunorubicin

Approved

Phase 2

20830-81-3

30323

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Interventional clinical trials:

(show top 50) (show all 155)

#	Name	Status	NCT ID	Phase	Drugs
1	HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)	Completed	NCT01418430	Phase 4	CHOP-daclizumab
2	HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens	Completed	NCT03226119	Phase 4
3	Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b	Terminated	NCT00854581	Phase 4	Valproic Acid;Zidovudine
4	An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma	Unknown status	NCT03553238	Phase 2, Phase 3	Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
5	An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia	Unknown status	NCT03564704	Phase 2, Phase 3	Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
6	Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801.	Completed	NCT00145002	Phase 3	VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis;biweekly-CHOP with G-CSF and intrathecal prophylaxis
7	A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients	Recruiting	NCT04446130	Phase 3	Decitabine combined with HAAG Regimen
8	Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia	Unknown status	NCT03613428	Phase 1, Phase 2	Ruxolitinib;Vincristine;Prednisone
9	A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens	Completed	NCT00489203	Phase 2	beclomethasone dipropionate;placebo;tacrolimus;methotrexate
10	Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma	Completed	NCT02631746	Phase 2
11	Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial	Completed	NCT00078858	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
12	A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil	Completed	NCT00089011	Phase 2	fludarabine phosphate;mycophenolate mofetil;tacrolimus
13	Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload	Completed	NCT01273766	Phase 2	deferasirox
14	Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation	Completed	NCT00049504	Phase 2	cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
15	Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies	Completed	NCT01839916	Phase 2
16	A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)	Completed	NCT01110135	Phase 2	bendamustine hydrochloride;dexamethasone;etoposide
17	Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil	Completed	NCT00006251	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
18	Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)	Completed	NCT01626664	Phase 2	Pralatrexate;gemcitabine plus oxaliplatin;DHAP
19	A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma	Completed	NCT00006473	Phase 2	oxaliplatin
20	A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma	Completed	NCT00131937	Phase 2	sorafenib tosylate
21	A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL)	Completed	NCT00005080	Phase 2	nelarabine
22	A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma	Completed	NCT00918333	Phase 1, Phase 2	panobinostat;everolimus
23	Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial	Completed	NCT00040846	Phase 2	fludarabine phosphate;mycophenolate mofetil;cyclosporine
24	Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma	Completed	NCT00920790	Phase 2
25	A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy	Completed	NCT01075321	Phase 1, Phase 2	everolimus;lenalidomide
26	Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial	Completed	NCT00118352	Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
27	Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma	Completed	NCT00082888	Phase 2	Tipifarnib
28	A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies	Completed	NCT00072514	Phase 2	gemcitabine hydrochloride;carboplatin;dexamethasone
29	Phase II Study of MK-2206 in Patients With Relapsed Lymphoma	Completed	NCT01258998	Phase 2	Akt inhibitor MK2206
30	A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Completed	NCT01261247	Phase 2	panobinostat
31	A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma	Completed	NCT01274533	Phase 2	Lenalidomide
32	Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma (Untreated Primary Disease)	Completed	NCT01173887	Phase 2	VCAP/AMP/VECP(mLSG15)
33	A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation	Completed	NCT01529827	Phase 2	fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
34	High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma	Completed	NCT01177371	Phase 2	busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
35	Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma	Completed	NCT01466881	Phase 2	Alisertib
36	A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation	Completed	NCT01427881	Phase 2	cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
37	A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma	Completed	NCT01724177	Phase 2	Lenalidomide
38	A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors	Completed	NCT01326702	Phase 1, Phase 2	Bendamustine Hydrochloride;Veliparib
39	Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma	Completed	NCT01378871	Phase 2	IMTOX-25
40	Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia	Completed	NCT00061048	Phase 2
41	A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia	Completed	NCT00001941	Phase 1, Phase 2
42	PHASE I/II STUDY OF TAC-EXPRESSING ADULT T-CELL LEUKEMIA (ATL) WITH YTTRIUM-90 (90Y)-RADIOLABELED HUMANIZED ANTI-TAC AND CALCIUM-DTPA	Completed	NCT00019227	Phase 1, Phase 2	pentetic acid calcium
43	Phase I/II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL)	Completed	NCT01712659	Phase 1, Phase 2	Ruxolitinib;ruxolitinib
44	A Phase 2b Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)	Completed	NCT02955589	Phase 2	HBI-8000
45	Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma	Completed	NCT00041327	Phase 2	Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine
46	Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma	Completed	NCT01000285	Phase 1, Phase 2	Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir
47	A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use	Completed	NCT00095381	Phase 2	forodesine hydrochloride (BCX-1777)
48	German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure	Completed	NCT00199030	Phase 2	Alemtuzumab (MabCampath);Cladribine
49	Phase I/II Study of RAD001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia, T-Cell Leukemia, or Mantle Cell Lymphoma	Completed	NCT00081874	Phase 1, Phase 2	RAD001
50	A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma	Completed	NCT00611208	Phase 2

Search NIH Clinical Center for Adult T-Cell Leukemia/lymphoma

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Adult T-Cell Leukemia/lymphoma cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Adult T-Cell Leukemia/lymphoma:

Hematopoietic stem cells for treatment of hematologic malignancies

Embryonic/Adult Cultured Cells Related to Adult T-Cell Leukemia/lymphoma:

Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: leukemia-lymphoma, adult t-cell

Sources

Genetic Tests for Adult T-Cell Leukemia/lymphoma

Sources

Anatomical Context for Adult T-Cell Leukemia/lymphoma

Organs/tissues related to Adult T-Cell Leukemia/lymphoma:

MalaCards : T Cells, Skin, Bone, Liver, Breast, Spleen, Bone Marrow

Sources

Publications for Adult T-Cell Leukemia/lymphoma

Articles related to Adult T-Cell Leukemia/lymphoma:

(show top 50) (show all 5847)

#	Title	Authors	PMID	Year
1	Production and characterization of an active single-chain variable fragment antibody recognizing CD25. ⁵³ ⁶²	Muramatsu H...Ueda R	15978327	2005
2	GPI-microdomains (membrane rafts) and signaling of the multi-chain interleukin-2 receptor in human lymphoma/leukemia T cell lines. ⁵³ ⁶²	Matko J...Damjanovich S	11856346	2002
3	Activation of interleukin-2 receptor alpha expression by extracellular HTLV-I Tax1 protein: a potential role in HTLV-I pathogenesis. ⁵³ ⁶²	Marriott SJ...Brady JN	1501887	1992
4	Hypercalcemia and production of parathyroid hormone-like protein in adult T-cell leukemia-lymphoma. ⁵³ ⁶²	Senba M...Kawai K	1644163	1992
5	HTLV-1 p27rex stabilizes human interleukin-2 receptor alpha chain mRNA. ⁵³ ⁶²	Kanamori H...Honjo T	2249670	1990
6	Rearrangement of human T cell receptor beta and gamma chain genes in adult T cell leukemia/lymphoma. ⁵³ ⁶²	Ohshima K...Satoh H	2160910	1990
7	ANK Therapeutic Prospects and Usefulness of PD-L1 and NK Activity as Biomarkers for Predicting Treatment Efficacy Revealed from the Treatment Course of Patients with HTLV-1-Associated Bronchioloalveolar Disease. ⁶²	Nagai K...Teshigawara K	36282976	2023
8	Increasing horizontal transmission of human T-cell leukemia virus type 1 in adolescents and young adults in Japan. ⁶²	Sagara Y...Hamaguchi I	36370501	2022
9	Regulation of human T-cell leukemia virus type 1 antisense promoter by myocyte enhancer factor-2C in the context of adult T-cell leukemia and lymphoma. ⁶²	Madugula KK...Jain P	35615924	2022
10	Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma. ⁶²	Hsu A...Carneiro BA	35815408	2022
11	Prognostic role of controlling nutritional status score in hematological malignancies. ⁶²	Zhang Y...Yu L	35622088	2022
12	Molecular insight into the study of adult T-cell leukemia/lymphoma (ATLL): Ten-year studies on HTLV-1 associated diseases in an endemic region. ⁶²	Ashrafi F...Abdolrahim Rezaee S	36108787	2022
13	A frequent PLCγ1 mutation in adult T-cell leukemia/lymphoma determines functional properties of the malignant cells. ⁶²	Prawiro C...Bangham CRM	36442790	2022
14	Landscape of immunoglobulin heavy chain gamma gene class switch recombination in patients with adult T-cell leukemia-lymphoma. ⁶²	Hiramatsu H...Ishida T	36420800	2022
15	Circulating clover-leaf cells presenting in acute-type adult T-cell leukemia-lymphoma. ⁶²	Lin YW...Lee MY	36467847	2022
16	Radiation Recall Dermatitis after Donor Lymphocyte Infusion for Adult T cell Leukemia Lymphoma post Allogeneic Stem Cell Transplant. ⁶²	Hardy-Abeloos C...Shaikh F	36347452	2022
17	Pseudo-progression of adult T-cell leukemia-lymphoma after cord blood transplantation. ⁶²	Fuji S...Ishikawa J	35734929	2022
18	HTLV-I associated bronchioloalveolar disorder (HABA): disease concept and differential diagnosis of an unsolved disease entity. ⁶²	Ohmoto A...Katsura K	36437745	2022
19	Endothelial function testing before conditioning therapy is useful for predicting transplant-related complications after allogeneic hematopoietic cell transplantation. ⁶²	Haji S...Ogawa Y	36436130	2022
20	CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma. ⁶²	Kameda T...Shimoda K	36446869	2022
21	Cholesterol metabolism and lipid droplet vacuoles; a potential target for the therapy of aggressive lymphoma. ⁶²	Yano H...Komohara Y	36436934	2022
22	Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas. ⁶²	Chiba M...Nakagawa M	35921533	2022
23	Development of a Novel HTLV-1 Protease: Human Fcγ1 Recombinant Fusion Molecule in the CHO Eukaryotic Expression System. ⁶²	Ahmadi Ghezeldasht S...Rezaee SA	36399306	2022
24	Establishment of a Cynomolgus Macaque Model of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Direct Inoculation of Adult T-Cell Leukemia Patient-Derived Cell Lines for HTLV-1 Infection. ⁶²	Urano E...Yasutomi Y	36314828	2022
25	Majocchi Granuloma in a Patient with Adult T-cell Leukemia. ⁶²	Ishibashi T...Fukushima S	36409384	2022
26	Acute type adult T-cell leukemia cells proliferate in the lymph nodes rather than in peripheral blood. ⁶²	Mizuguchi M...Tanaka Y	35459881	2022
27	Frequency and characteristics of HTLV in migrants: results from the +Redivi collaborative network in Spain. ⁶²	Norman FF...Lopez-Velez R	35166822	2022
28	Selective APC-targeting of a novel Fc-fusion multi-immunodominant recombinant protein (tTax-tEnv:mFcγ2a) for HTLV-1 vaccine development. ⁶²	Shafifar M...Rezaee SA	36044973	2022
29	Valemetostat Tosilate: First Approval. ⁶²	Keam SJ	36380144	2022
30	Diagnostic utility of the aberrant immunohistochemical expression of CD3 molecules for peripheral T-cell lymphomas. ⁶²	Satoh T...Yasuda M	35905535	2022
31	Breast T-Lymphoblastic Lymphoma Presenting as a Single Mass in a Young Female with Family History of Breast Cancer. ⁶²	Iqbal F...Lyapichev KA	35188824	2022
32	Live attenuated VZV vaccination induces antitumor immunity in ATLL patients. ⁶²	Jo T...Shigematsu K	36181532	2022
33	Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study. ⁶²	Imaizumi Y...Tsukasaki K	36308678	2022
34	Primary Effusion Lymphoma-like ATL Developing During Hemodialysis. ⁶²	Masaki M...Masaki Y	36261387	2022
35	HTLV infection in Brazil's second-largest indigenous reserve. ⁶²	Amianti C...Motta-Castro ARC	36202887	2022
36	Diagnosis and Early Prediction of Lymphoma Using High-Throughput Clonality Analysis of Bovine Leukemia Virus-Infected Cells. ⁶²	Okagawa T...Ohashi K	36227090	2022
37	Clinicopathological analysis of immunohistochemical expression of immune checkpoint molecules in follicular lymphoma. ⁶²	Yanagida E...Ohshima K	35122292	2022
38	Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. ⁶²	Tanaka N...Ishida T	35417939	2022
39	[Clinical Study of Chemotherapy Combined with Antivirals for Adult T-cell Leukemia/Lymphoma]. ⁶²	Lin Y...Chen Q	36208242	2022
40	The importance of the clinical classification of adult T-cell leukemia/lymphoma (ATLL) in the prognosis. ⁶²	Oliveira PD...Bittencourt AL	36260617	2022
41	ETS1 is a novel transcriptional regulator of adult T-cell leukemia/lymphoma of North American descent. ⁶²	Luchtel RA...Maqbool SB	35675522	2022
42	Signaling factors potentially associated to the pathogenesis of Adult T-cell leukemia /lymphoma: A network-analysis and novel findings assessment. ⁶²	Mozhgani SH...Rezaee SA	35868352	2022
43	Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma. ⁶²	Dou F...Gao J	36310058	2022
44	Gamma-secretase inhibitor does not induce cytotoxicity in adult T-cell leukemia cell lines despite NOTCH1 expression. ⁶²	Suzuki S...Ishitsuka K	36243685	2022
45	Particularities of Neurological Manifestations in Adult T-Cell Leukemia/Lymphoma: Need for a Multidisciplinary Approach-A Narrative Review. ⁶²	Iordan I...Bumbea H	36363509	2022
46	TCL-150 Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma. ⁶²	Narvel H...Sica RA	36164124	2022
47	Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study. ⁶²	Hirosawa M...Tsukada J	36083572	2022
48	Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract. ⁶²	Tsubokura Y...Nomura S	36039651	2022
49	Alvocidib inhibits IRF4 expression via super-enhancer suppression and adult T-cell leukemia/lymphoma cell growth. ⁶²	Sakamoto H...Miyazaki Y	36047964	2022
50	HTLV-1-related adult T-cell leukemia/lymphoma: insights in early detection and management. ⁶²	Wolf S...Cook L	35880453	2022

Sources

Genes for Adult T-Cell Leukemia/lymphoma

Genes related to Adult T-Cell Leukemia/lymphoma (0 elite genes):

(show all 39)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	BCL11B	BCL11 Transcription Factor B	Protein Coding	22.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Expressions (show sections)
2	EPC1	Enhancer Of Polycomb Homolog 1	Protein Coding	21.63	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
3	CNTN2	Contactin 2	Protein Coding	16.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1501887
4	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	14.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15978327 2249670 11856346
5	PTHLH	Parathyroid Hormone Like Hormone	Protein Coding	13.22	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1644163
6	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	9.55	DISEASES inferred ¹⁴ ¹⁴
7	HBZ	Hemoglobin Subunit Zeta	Protein Coding	8.85	DISEASES inferred ¹⁴
8	MIR155	MicroRNA 155	RNA Gene	8.54	DISEASES inferred ¹⁴ ¹⁴
9	CD4	CD4 Molecule	Protein Coding	7.9	DISEASES inferred ¹⁴
10	H2AC18	H2A Clustered Histone 18	Protein Coding	7.37	DISEASES inferred ¹⁴ ¹⁴
11	IL2	Interleukin 2	Protein Coding	7.28	DISEASES inferred ¹⁴
12	CD8A	CD8a Molecule	Protein Coding	7.26	DISEASES inferred ¹⁴
13	KDM4C	Lysine Demethylase 4C	Protein Coding	7.05	DISEASES inferred ¹⁴ ¹⁴
14	MIR28	MicroRNA 28	RNA Gene	7.04	DISEASES inferred ¹⁴ ¹⁴
15	TNFRSF8	TNF Receptor Superfamily Member 8	Protein Coding	6.96	DISEASES inferred ¹⁴
16	CD7	CD7 Molecule	Protein Coding	6.94	DISEASES inferred ¹⁴
17	CENPV	Centromere Protein V	Protein Coding	6.94	DISEASES inferred ¹⁴
18	CD2	CD2 Molecule	Protein Coding	6.62	DISEASES inferred ¹⁴
19	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	6.56	DISEASES inferred ¹⁴ ¹⁴
20	ATL2	Atlastin GTPase 2	Protein Coding	6.56	DISEASES inferred ¹⁴
21	SERPINH1	Serpin Family H Member 1	Protein Coding	6.52	DISEASES inferred ¹⁴
22	CREB1	CAMP Responsive Element Binding Protein 1	Protein Coding	6.46	DISEASES inferred ¹⁴
23	TP53	Tumor Protein P53	Protein Coding	6.45	DISEASES inferred ¹⁴
24	JUND	JunD Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	6.44	DISEASES inferred ¹⁴
25	MIR142	MicroRNA 142	RNA Gene	6.42	DISEASES inferred ¹⁴ ¹⁴
26	CD5	CD5 Molecule	Protein Coding	6.34	DISEASES inferred ¹⁴
27	FOXP3	Forkhead Box P3	Protein Coding	6.33	DISEASES inferred ¹⁴
28	IRF4	Interferon Regulatory Factor 4	Protein Coding	6.3	DISEASES inferred ¹⁴
29	CCR4	C-C Motif Chemokine Receptor 4	Protein Coding	6.26	DISEASES inferred ¹⁴
30	CADM1	Cell Adhesion Molecule 1	Protein Coding	6.21	DISEASES inferred ¹⁴
31	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	6.16	DISEASES inferred ¹⁴
32	CTLA4	Cytotoxic T-Lymphocyte Associated Protein 4	Protein Coding	6.12	DISEASES inferred ¹⁴
33	IKBKG	Inhibitor Of Nuclear Factor Kappa B Kinase Regulatory Subunit Gamma	Protein Coding	6.11	DISEASES inferred ¹⁴
34	CARD11	Caspase Recruitment Domain Family Member 11	Protein Coding	6.1	DISEASES inferred ¹⁴
35	EP300	E1A Binding Protein P300	Protein Coding	6.08	DISEASES inferred ¹⁴
36	BCL2	BCL2 Apoptosis Regulator	Protein Coding	6.03	DISEASES inferred ¹⁴
37	TXN	Thioredoxin	Protein Coding	6.03	DISEASES inferred ¹⁴
38	CCL22	C-C Motif Chemokine Ligand 22	Protein Coding	6.03	DISEASES inferred ¹⁴
39	IL15	Interleukin 15	Protein Coding	6.02	DISEASES inferred ¹⁴

Sources

Variations for Adult T-Cell Leukemia/lymphoma

Sources

Expression for Adult T-Cell Leukemia/lymphoma

Search GEO for disease gene expression data for Adult T-Cell Leukemia/lymphoma.

Sources

Pathways for Adult T-Cell Leukemia/lymphoma

Pathways related to Adult T-Cell Leukemia/lymphoma according to GeneCards Suite gene sharing:

(show all 13)

#	Super pathways	Score	Top Affiliating Genes
1	NF-kappaB Signaling ³	12.15	TNFRSF8 IL2RA IL2 CD8A CD2 BCL11B
2	CD28 Signaling in T-Helper Cell ⁶⁴ Show member pathways ICos-ICosL Pathway in T-Helper Cell ⁶⁴	11.98	IL2RA IL2 ICOSLG CD4
3	IL12-mediated signaling events ⁶¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²²	11.67	IL2RA IL2 CD8A CD4
4	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.54	CD8A CD4 CD2
5	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.5	IL2 CD8A CD4
6	Th17 cell differentiation pathway ⁷⁴	11.45	IL2RA IL2 CD4
7	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.42	IL2RA IL2 CD8A CD4 CD2
8	Th2 Differentiation ⁶⁵	11.21	CD4 IL2 IL2RA
9	Innate Lymphoid Cells Differentiation ⁶⁵	11	IL2RA IL2 CD8A CD7 CD4 CCR6
10	IL12 signaling mediated by STAT4 ⁶¹	10.86	IL2RA IL2 CD4
11	Selective expression of chemokine receptors during T-cell polarization ⁷⁴	10.7	IL2 CD4
12	RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) ⁶⁶	10.51	IL2RA IL2
13	COVID-19 adverse outcome pathway ⁷⁴	10.49	IL2RA IL2

Sources

GO Terms for Adult T-Cell Leukemia/lymphoma

Cellular components related to Adult T-Cell Leukemia/lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	external side of plasma membrane	GO:0009897	9.4	IL2RA ICOSLG CD8A CD4 CD2 CCR6

Biological processes related to Adult T-Cell Leukemia/lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	immune response	GO:0006955	10.15	IL2RA IL2 CD8A CD7 CD4 CCR6
2	immune system process	GO:0002376	9.8	IL2RA IL2 ICOSLG CD8A CD7 CD4
3	positive regulation of activated T cell proliferation	GO:0042104	9.63	IL2RA IL2 ICOSLG
4	negative regulation of lymphocyte proliferation	GO:0050672	9.58	IL2RA IL2
5	regulation of T cell homeostatic proliferation	GO:0046013	9.56	IL2 IL2RA
6	T cell activation	GO:0042110	9.32	ICOSLG CD8A CD7 CD4 CD2
7	regulation of CD4-positive, alpha-beta T cell proliferation	GO:2000561	9.26	IL2RA IL2